Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,513.12% | 124.23% | 316.72% | 103.95% | 87.15% |
| Total Depreciation and Amortization | 1.45% | 2.13% | 2.04% | 2.08% | 0.32% |
| Total Amortization of Deferred Charges | 10.61% | 5.33% | 5.10% | 4.98% | 1.61% |
| Total Other Non-Cash Items | 735.62% | -6.82% | 46.24% | 169.88% | 22.65% |
| Change in Net Operating Assets | 4.08% | 93.47% | 21.31% | 810.39% | -103.19% |
| Cash from Operations | 4,440.11% | 198.39% | 914.84% | 321.94% | 101.76% |
| Capital Expenditure | 25.09% | -2,400.00% | -51.36% | 18.39% | 29.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 25.09% | -2,400.00% | -103.32% | -100.72% | -106.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18.42% | 68.28% | 125.89% | -- | 153.80% |
| Repurchase of Common Stock | 77.79% | -112.77% | -827.71% | -475.90% | -1,586.27% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 106.26% | -181.70% | -166.83% | 16,786.75% | 42.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,083.08% | 105.37% | 56.95% | 2,010.81% | 116.61% |